At a glance
ClinicalIndex Comparison RecordN/ACompleted· 272 enrolled
Drug / intervention
Zepzelcadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Jazz Emerge 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
In Brief
An observational study evaluating Zepzelca for Extensive-stage Small-cell Lung Cancer. Completed, enrolled 272 participants across 41 sites in 2 countries.
Detailed Summary
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small-cell Lung Cancer
CountriesCanada, United States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartJun 2021
Primary CompletionJun 2025
TodayJul 2026
First PostedMay 20, 2021
Enrollment StartJun 28, 2021
Primary CompletionJun 4, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.1 years ago
Interventions
Zepzelcadrug
Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.